Corbus Pharmaceuticals Holdings, Inc. income statement

In fiscal 2022, Corbus Pharmaceuticals Holdings, Inc. reported revenue of $0, down 100.0% on the year before and net income of −$42.3m, or −$10.15 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Corbus Pharmaceuticals Holdings, Inc.: income statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022
Revenue	1	2	2	5	36	4	1	0
Research and development	6	15	26	49	90	98	36	16
General and administrative	4	6	9	13	24	28	20	19
Operating income	−9	−20	−33	−57	−77	−123	−56	−40
Interest expense	0	0	0	—	0	1	3	3
Net interest income	—	—	—	—	1	−1	−2	−2
Net income	−9	−20	−32	−56	−71	−111	−46	−42
Diluted EPS	−$8.40	−$14.70	−$19.50	−$29.40	−$33.60	−$42.60	−$11.15	−$10.15
Diluted shares (average)	1m	1m	2m	2m	2m	3m	4m	4m
EBITDA	−9	−20	−32	−56	−76	−122	−55	−39

US$ millions unless shown otherwise. Fiscal quarters.

Corbus Pharmaceuticals Holdings, Inc.: income statement, quarterly
Quarter	2020 Q4Dec 2020	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Revenue	1	1	0	0	0	0	0	0
Research and development	16	11	11	9	0	3	4	6
General and administrative	5	5	6	5	0	5	4	5
Operating income	−21	−15	−17	−14	−10	−9	−8	−11
Interest expense	1	1	1	1	1	1	1	1
Net interest income	−1	−1	−0	−0	−0	−0	−1	−1
Net income	−9	−16	−17	−2	−10	−9	−9	−11
Diluted EPS	−$1.50	−$4.20	−$4.50	−$0.60	−$10.86	−$2.26	−$2.11	−$2.60
EBITDA	−21	−15	−16	−14	−10	−8	−8	−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Corbus Pharmaceuticals Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Corbus Pharmaceuticals Holdings, Inc.